$SION

Vertex Pharmaceuticals (VRTX) maintains dominance in the cystic fibrosis (CF) drug market. Sionna Therapeutics (SION) reported a phase 2 trial failure for its CF drug candidate, SION-719, causing its stock to drop 90%. Vertex's CF drugs, including Trikafta and Alyftrek, now target 95% of CF patients. Vertex is also expanding into other therapeutic areas, such as gene-editing therapy Casgevy for sickle cell disease and beta-thalassemia, developed with CRISPR Therapeutics (CRSP).

Sionna Therapeutics (SION) shares fell about 92% after it said its Phase 2a trial of SION-719 in 15 cystic fibrosis adults failed to meet its main goal. The add-on drug did not significantly improve sweat chloride versus placebo, so Sionna will not advance it. SION had $268M cash. Analysts cited reduced overhang for Vertex (VRTX).

Sionna Therapeutics (NASDAQ:SION) shares fell over 90% after its Phase 2a PreciSION CF trial of SION-719 as an add-on to Vertex’s Trikafta failed its main activity endpoint, so Sionna said it will not proceed SION-719. Vertex (NASDAQ:VRTX) rose to new highs as the CF competitive overhang eased. Sionna will prioritize SION-451; Vertex cited prior strength and guidance.

Sionna Therapeutics (Nasdaq: SION) said its PreciSION CF Phase 2a study of SION-719, tested as an add-on to Trikafta, did not meet the key activity endpoint of sweat chloride reduction. The company discontinued SION-719 development in that role, according to the company. The article also references other SION updates and financial results.

Sionna Therapeutics Inc. (NASDAQ:SION) reported top-line Phase IIa data for two nucleotide binding domain 1 stabilizer programs in cystic fibrosis, and said the programs did not meet expectations. Shares fell sharply, closing Aug. 10 at $4.50, down $46.54 (91%), according to the report.

Sionna Therapeutics said its experimental cystic fibrosis pill SION-719, tested as an add-on to Vertex Pharmaceuticals’ Trikafta, showed no benefit in a Phase 2 trial. Sionna will not advance SION-719 as an add-on therapy and said it may take actions to preserve capital, including potential layoffs. Sionna’s stock fell about 90% pre-market.

Sionna Therapeutics said its Phase 2a PreciSION trial of SION-719, an add-on to Vertex’s Trikafta for cystic fibrosis, failed to meet its goal. In 15 patients, sweat chloride changed by -1.0 mmol/L, not statistically significant versus a 10 mmol/L target, and Sionna will discontinue SION-719. Sionna shares fell over 90% premarket; Vertex shares rose about 6%.

US equity futures largely gave back overnight gains after oil hit a one-week high and the yen weakened. Traders await US CPI and PPI, with rate-hike bets cooling after Friday’s jobs report. JPMorgan raised its S&P 500 year-end target to 8000. Corporate movers include AAON (+8%), ABCL (+22%), HZO halted on a $53 buyout, and VREX surging on Teledyne’s $18.90 offer.

Sionna Therapeutics (SION) said its Phase 2a PreciSION CF study of SION-719 added to Trikafta in cystic fibrosis did not meet the primary endpoint. The mean placebo-adjusted sweat chloride change was 1.0 mmol/L and not statistically significant. Sionna will not advance SION-719 as an add-on. Cash was about $268.3M. Shares fell about 90%.

U.S. stock index futures edged higher as investors weighed fading Middle East deal hopes and upcoming inflation data. Tenax Therapeutics shares fell 84.2% after Phase 3 TNX-103 missed endpoints. Sionna Therapeutics dropped 92.1% after Phase 2a SION-719 failed. MarineMax rose over 34% on a reported $1.5B Safe Harbor Marinas buyout. AAON, Silence, Dole, and AirSculpt also moved premarket on updates.